Sanofi: Innovation Leader in Immunology Thanks to Blueprint Acquisition!
Reading Time: 3 minutes
On Monday, Sanofi announced that it will acquire the US biopharmaceutical company Blueprint Medicines Corporation for a total amount of up to $9.5 billion. The agreement includes a cash payment of $129 per share. Additionally, Blueprint shareholders will receive two potential milestone payments that could allow for further payments of up to $6 per share upon achieving certain regulatory and commercial targets. Blueprint brings a unique drug to the table with Ayvakit With this acquisition, Sanofi is specifically strengthening its portfolio...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
